About this trial
Fibromyalgia is a chronic pain syndrome characterized by widespread musculoskeletal pain, fatigue, sleep disturbances, and cognitive symptoms. Central sensitization is considered a key mechanism in the pathophysiology of fibromyalgia; however, the underlying biological markers have not been fully clarified.
Brain-derived neurotrophic factor (BDNF) and S100B protein have been suggested to play roles in neuroinflammation and central pain processing. This observational, cross-sectional study aims to evaluate serum S100B and BDNF levels in patients with fibromyalgia and to investigate their relationship with central sensitization and sleep quality. Serum biomarker levels and clinical assessment scales will be compared between patients with fibromyalgia and healthy controls.
Eligibility criteria
This trial accepts healthy volunteersQualifiers
Female participants aged between 18 and 50 years
Disqualifiers
None
Trial population
Presence of any systemic disease (hematologic, endocrine, rheumatologic, renal, cardiovascular, gastrointestinal, or respiratory) Active infection History of malignancy Major surgery or trauma within the last 1 year Any treatment for fibromyalgia within the last 3 months Pregnancy or breastfeeding Smoking Vitamin D deficiency
Trial design
Other
Prospective
Treatments tested in this trial
No Intervention (Observational Study)
Other interventionThis is an observational study with no therapeutic or diagnostic intervention. Participants will undergo a single-time-point clinical assessment and venous blood sampling for biomarker measurement only.
Treatment groups
Trial outcomes
Primary outcomes
Association between serum S100B and serum BDNF
Serum S100B and serum BDNF concentrations will be measured from venous blood samples and the strength of association between the two biomarkers will be analyzed
Secondary outcomes
Correlation of serum S100B and BDNF with Central Sensitization Inventory (CSI)
Serum S100B and BDNF levels will be correlated with CSI total score to evaluate biomarker association with central sensitization severity.
Correlation of serum S100B and BDNF with Pittsburgh Sleep Quality Index (PSQI)
Serum S100B and BDNF levels will be correlated with PSQI total score to evaluate association with sleep quality.
Sponsors and contacts
Click on the lead sponsor to view all of their trials.